Business Context and Reporting Period
Company: Merit Medical Systems, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2009
Overview: Merit Medical Systems is a manufacturer of medical devices. The quarter was characterized by record revenues driven by organic growth and the strategic acquisition of Alveolus, Inc. and Biosearch Medical Products, Inc., expanding the company's presence in gastroenterology and pulmonary markets.
Key Financial Metrics
| Metric | Q1 2009 | Q1 2008 |
|---|---|---|
| Net Sales | $58,371,000 | $53,553,000 |
| Gross Profit | $24,808,000 | $21,592,000 |
| Gross Margin | 42.5% | 40.3% |
| Operating Income | $7,900,000 | $6,604,000 |
| Net Income | $5,537,000 | $4,317,000 |
| Diluted EPS | $0.19 | $0.15 |
| Cash from Operations | $9,348,000 | $9,640,000 |
| Cash and Equivalents (End of Period) | $16,430,000 | $23,757,000 |
| Working Capital | $67,425,000 | $84,283,000 |
| Current Ratio | 3.5:1 | N/A |
| Long-Term Debt | $0 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% ($4.8 million) year-over-year. Growth was driven by custom kits, catheters, stand-alone devices, and stent sales from the Alveolus acquisition. This offset a 1.8% decrease in sales due to foreign exchange rates and a 1.2% decline in inflation device sales to an OEM.
- Margin Expansion: Gross margin improved to 42.5% from 40.3%. Drivers included lower fixed overhead unit costs due to higher productivity, reduced material costs, and a favorable Euro-to-U.S. Dollar exchange rate.
- Profitability: Net income rose 28% to $5.5 million, aided by higher sales, improved margins, and a lower effective tax rate (31.4% vs. 36.0% in 2008).
- Acquisitions: The company completed the acquisition of Alveolus (non-vascular stents) for $19.1 million and Biosearch (bipolar coagulation probe and biliary stents) for $1.6 million. These transactions significantly increased goodwill and intangible assets.
- Liquidity: Cash and cash equivalents decreased by $17.6 million, primarily due to $20.2 million in acquisition costs and $2.5 million in common stock repurchases.
Guidance, Outlook, and Risks
Management Commentary: Management expects to continue implementing automation and manufacturing cost-saving improvements. They anticipate that new products introduced through organic growth and acquisitions will increase average product margins. The company believes current liquidity sources are adequate for foreseeable operations.
Risks and Contingencies:
- Integration Risk: Unanticipated consequences from recent acquisitions (Alveolus and Biosearch) and the challenge of managing growth.
- Market Risk: Exposure to fluctuations in the Euro and Great Britain Pound relative to the U.S. Dollar. A weaker foreign currency reduced revenues by approximately $1.0 million in the quarter.
- Regulatory and Product Risk: Potential delays in regulatory approvals, product recalls, liability claims, and the risk of new technologies rendering current products obsolete.
- Concentration: Revenue concentration among a few products and procedures.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of Alveolus and Biosearch assets and the realization of projected synergies.
- Intangible Asset Amortization: Monitor the impact of amortization on future earnings from the $17.3 million in net intangible assets and $21.1 million in goodwill recognized.
- Foreign Exchange Exposure: Assess the company's hedging strategies and the potential impact of currency fluctuations on future margins.
- Inventory Levels: Review inventory turnover given the increase in inventory to $42.9 million and the risk of obsolescence for new product lines.
- Stock Repurchase Program: Track the remaining authorized shares for repurchase (1,029,942 shares remaining as of March 31, 2009) and its impact on cash flow.